Know what’s really happening at
Kopra Bio before you sign on.
- On the roadmap
- Cancer Immunotherapy
- Biotechnology
- Oncology
Kopra Bio is developing a proprietary viral immunotherapy platform that reprograms cancer cells into biofactories for their own destruction, starting with glioblastoma — one of the most aggressive and treatment-resistant brain cancers. Backed by Y Combinator and notable investors including Paul Graham, the company is advancing technology originally developed at UCSF.
How we do it.
Most "AI market intel" is a summarized crawl of press releases. This Altis research is built from our knowledge graph of sector expert calls, synthesized with public sources.
Kopra Bio
- Year Founded
- 2024
- Total Funding
- $9.7M
- Last Round (Seed, June 2026)
- $9.1M
- Employee Count
- 21
- Headquarters
- San Francisco, California, United States
- Lead Investor
- Y Combinator
- Founder
- Manish Aghi
Press reported
Altis Verified
What's in the report
Most "AI market intel" is a summarized crawl of press releases. This is what customers, competitors, and former employees actually told us.
Market Overview
Market structure, where the company sits, and growth drivers.
- market map
- Cancer Immunotherapy landscape
- Cancer Immunotherapy growth rate
- CAGR
Total Addressable Market
Bottom-up TAM / SAM / SOM.
- Kopra Bio TAM
- Cancer Immunotherapy market size
- market opportunity
Company Overview
What the company does and how it operates.
- what does Kopra Bio do
- Kopra Bio product
- business model
Product / Go-to-Market
Product, GTM motion, ICP, and who buys.
- Kopra Bio customers
- who uses Kopra Bio
- Kopra Bio ICP
- go-to-market
Competitive Dynamics
The Altis Market Map and the Altis Win-Rate Index.
- Kopra Bio competitors
- Kopra Bio alternatives
- who competes with Kopra Bio
- Kopra Bio win rate
Customer Signals
Retention, satisfaction, and win/loss signals.
- Kopra Bio reviews
- Kopra Bio NRR
- Kopra Bio churn
- current customers
- switching costs
Investment Debates
Investment thesis, moat, bull/bear, and key risks.
- Kopra Bio investment thesis
- Kopra Bio moat
- bull case bear case
- Kopra Bio risk factors
Monetization & Financials
Business model, revenue model, and unit economics.
- Kopra Bio ARR
- Kopra Bio revenue
- Kopra Bio valuation
- unit economics
Team and culture
Founders, leadership, and org.
- Kopra Bio founders
- Kopra Bio CEO background
- leadership team
- headcount
Trusted by
Ready to see the full picture?
This page is based on publicly available company profile data and Altis screening research.